文献速递流行病学与生物统计临床试验与 GCP

英国临床试验获取常规收集健康数据的系统性综述

Access to routinely collected health data for clinical trials - review of successful data requests to UK registries.
PubMed 文献 · Trials · 2020-05-12

该系统综述检索2013至2018年英国注册库中获取常规收集健康数据(RCHD)的随机对照试验(RCT),共识别160项RCT,仅占英国全部RCT约3%。这些试验多为大型试验(中位样本量1590),主要用于癌症或心血管疾病治疗评价,最常获取死亡率和住院数据,用于主要试验告知和长期随访。

要点

  • 仅约3%的英国RCT获取RCHD,比例极低。
  • 获取RCHD的RCT多为大型试验,中位样本量1590。
  • 最常获取死亡率(76%)和住院数据(55%)。

核心结论

  • 过去五年仅少数英国RCT获取RCHD用于参与者数据。
  • 呼吁注册库和监管机构改善可及性、确认数据质量并加强协同。

研究设计与样本

  • 系统综述,检索2013至2018年英国至少一个注册库中获取RCHD的RCT。
  • 共识别160项RCT,来自22个注册库,检索和数据提取于2019年1月至5月进行。

主要发现

  • 获取RCHD的RCT仅占英国全部RCT约3%。
  • 中位样本量1590,常见评估癌症或心血管疾病治疗。
  • 68%的RCT从NHS Digital获取RCHD,最常获取死亡率(76%)和住院就诊(55%)数据。
  • RCHD用于告知主要试验占82%,用于长期随访占57%。
  • RCT利用RCHD告知参与者结局指标的方式存在较大差异。

临床怎么用

  • 临床试验可考虑利用RCHD补充参与者数据,尤其是死亡率和住院结局。
  • 需关注注册库数据可及性和透明度,以支持RCHD在试验中的应用。

局限性

  • 注册库和RCT对获取哪些数据集及目的缺乏信息和透明度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials generally each collect their own data despite routinely collected health data (RCHD) increasing in quality and breadth. Our aim is to quantify UK-based randomised controlled trials (RCTs) accessing RCHD for participant data, characterise how these data are used and thereby recommend how more trials could use RCHD. METHODS: We conducted a systematic review of RCTs accessing RCHD from at least one registry in the UK between 2013 and 2018 for the purposes of informing or supplementing participant data. A list of all registries holding RCHD in the UK was compiled. In cases where registries published release registers, these were searched for RCTs accessing RCHD. Where no release register was available, registries were contacted to request a list of RCTs. For each identified RCT, information was collected from all publicly available sources (release registers, websites, protocol etc.). The search and data extraction were undertaken between January and May 2019. RESULTS: We identified 160 RCTs accessing RCHD between 2013 and 2018 from a total of 22 registries; this corresponds to only a very small proportion of all UK RCTs (about 3%). RCTs accessing RCHD were generally large (median sample size 1590), commonly evaluating treatments for cancer or cardiovascular disease. Most of the included RCTs accessed RCHD from NHS Digital (68%), and the most frequently accessed datasets were mortality (76%) and hospital visits (55%). RCHD was used to inform the primary trial (82%) and long-term follow-up (57%). There was substantial variation in how RCTs used RCHD to inform participant outcome measures. A limitation was the lack of information and transparency from registries and RCTs with respect to which datasets have been accessed and for what purposes. CONCLUSIONS: In the last five years, only a small minority of UK-based RCTs have accessed RCHD to inform participant data. We ask for improved accessibility, confirmed data quality and joined-up thinking between the registries and the regulatory authorities. TRIAL REGISTRATION: PROSPERO CRD42019123088.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lensen S, Macnair A, Love SB, et al. Access to routinely collected health data for clinical trials - review of successful data requests to UK registries. Trials. 2020. PMID: 32398093. doi:10.1186/s13063-020-04329-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。